BC014781
[Other Products]
UniProt Secondary Accession #
UniProt Related Accession #
Molecular Weight
49,578 Da
NCBI Official Full Name
Homo sapiens lecithin-cholesterol acyltransferase, mRNA
NCBI Official Synonym Full Names
lecithin-cholesterol acyltransferase
NCBI Protein Information
phosphatidylcholine-sterol acyltransferase
UniProt Protein Name
Phosphatidylcholine-sterol acyltransferase
UniProt Synonym Protein Names
Lecithin-cholesterol acyltransferase; Phospholipid-cholesterol acyltransferase
UniProt Entry Name
LCAT_HUMAN
NCBI Summary for LCAT
This gene encodes the extracellular cholesterol esterifying enzyme, lecithin-cholesterol acyltransferase. The esterification of cholesterol is required for cholesterol transport. Mutations in this gene have been found to cause fish-eye disease as well as LCAT deficiency. [provided by RefSeq, Jul 2008]
UniProt Comments for LCAT
LCAT: Central enzyme in the extracellular metabolism of plasma lipoproteins. Synthesized mainly in the liver and secreted into plasma where it converts cholesterol and phosphatidylcholines (lecithins) to cholesteryl esters and lysophosphatidylcholines on the surface of high and low density lipoproteins (HDLs and LDLs). The cholesterol ester is then transported back to the liver. Has a preference for plasma 16:0-18:2 or 18:O-18:2 phosphatidylcholines. Also produced in the brain by primary astrocytes, and esterifies free cholesterol on nascent APOE-containing lipoproteins secreted from glia and influences cerebral spinal fluid (CSF) APOE- and APOA1 levels. Together with APOE and the cholesterol transporter ABCA1, plays a key role in the maturation of glial-derived, nascent lipoproteins. Required for remodeling high-density lipoprotein particles into their spherical forms. Defects in LCAT are the cause of lecithin-cholesterol acyltransferase deficiency (LCATD); also called Norum disease. LCATD is a disorder of lipoprotein metabolism characterized by inadequate esterification of plasmatic cholesterol. Two clinical forms are recognized: familial LCAT deficiency and fish-eye disease. Familial LCAT deficiency is associated with a complete absence of alpha and beta LCAT activities and results in esterification anomalies involving both HDL (alpha-LCAT activity) and LDL (beta-LCAT activity). It causes a typical triad of diffuse corneal opacities, target cell hemolytic anemia, and proteinuria with renal failure. Defects in LCAT are a cause of fish-eye disease (FED); also known as dyslipoproteinemic corneal dystrophy or alpha-LCAT deficiency. FED is due to a partial LCAT deficiency that affects only alpha-LCAT activity. It is characterized by low plasma HDL and corneal opacities due to accumulation of cholesterol deposits in the cornea ('fish-eye'). Belongs to the AB hydrolase superfamily. Lipase family.
Protein type: Secreted, signal peptide; Lipid Metabolism - glycerophospholipid; Transferase; Secreted; EC 2.3.1.43
Chromosomal Location of Human Ortholog: 16q22.1
Cellular Component: extracellular region; extracellular space
Molecular Function: apolipoprotein A-I binding; phosphatidylcholine-sterol O-acyltransferase activity; protein binding
Biological Process: cholesterol homeostasis; cholesterol metabolic process; cholesterol transport; lipoprotein metabolic process; phosphatidylcholine biosynthetic process; phosphatidylcholine metabolic process; phospholipid metabolic process; reverse cholesterol transport
Disease: Fish-eye Disease; Lecithin:cholesterol Acyltransferase Deficiency
Research Articles on LCAT
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice. It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Pathways associated with LCAT cdna clone
Diseases associated with LCAT cdna clone
Organs/Tissues associated with LCAT cdna clone
|